.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ASCLEPIOS I and II phase 3 trials compared the B-cell-depleting monoclonal antibody ofatumumab with oral teriflunomide in patients with relapsing multiple sclerosis. Across the two studies, ofatumumab significantly reduced the annualised relapse rate and MRI evidence of new inflammatory disease compared with teriflunomide. The treatment effect was consistent across a broad relapsing-MS population and was accompanied by a manageable safety profile. The biological rationale is that selective depletion of CD20-positive B cells reduces immune activity implicated in multiple sclerosis. For HCPs, the clinical importance is that highly effective disease-modifying therapy can be delivered subcutaneously at home rather than through an infusion centre. The decision to use ofatumumab still requires attention to infection risk, vaccination status, immunoglobulin levels and patient preference. The trial also illustrates a wider change in MS treatment strategy: rather than escalating slowly through less effective agents in every patient, some patients may benefit from earlier use of a high-efficacy therapy. This is relevant to IANCON's emphasis on future-facing, disease-modifying neurology and precision treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ASCLEPIOS I and II phase 3 trials compared the B-cell-depleting monoclonal antibody ofatumumab with oral teriflunomide in patients with relapsing multiple sclerosis. Across the two studies, ofatumumab significantly reduced the annualised relapse rate and MRI evidence of new inflammatory disease compared with teriflunomide. The treatment effect was consistent across a broad relapsing-MS population and was accompanied by a manageable safety profile. The biological rationale is that selective depletion of CD20-positive B cells reduces immune activity implicated in multiple sclerosis. For HCPs, the clinical importance is that highly effective disease-modifying therapy can be delivered subcutaneously at home rather than through an infusion centre. The decision to use ofatumumab still requires attention to infection risk, vaccination status, immunoglobulin levels and patient preference. The trial also illustrates a wider change in MS treatment strategy: rather than escalating slowly through less effective agents in every patient, some patients may benefit from earlier use of a high-efficacy therapy. This is relevant to IANCON's emphasis on future-facing, disease-modifying neurology and precision treatment.
last month
Preclinical findings demonstrate that ginsenoside Ra1 preserves vascular integrity and attenuates multi-organ injury during sepsis by targeting non-muscle myosin heavy chain IIA (NMMHC IIA) and dampening TLR4/NF-κB/NLRP3 inflammatory signaling.
2 days back
An all-printed immunosensing microchip detects urinary sFlt-1 in just 10 minutes with 3.61 pg/mL sensitivity. By leveraging photonic bandgap engineering, this low-cost, cleanroom-free platform provides non-invasive preeclampsia screening, offering substantial benefits for point-of-care obstetric triage.
3 days back
Wearable ultrasound patches are transforming healthcare by shifting medicine from episodic evaluations to continuous monitoring. Discover how flexible acoustic transducers advance cardiovascular tracking, musculoskeletal imaging, neuromodulation, and on-demand closed-loop theranostics.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
